ALACT — Acticor Biotech SA Share News
0.000.00%
Last trade - 00:00Brief: Acticor Biotech/Glenzocimab: Analysis Of Primary And Secondary Endpoints Of Phase 2/3 Actisave Showed No Improved Efficacy
Brief: Acticor Biotech Launches Capital Increase Of Minimum Of EUR 7 Mln
Brief: Acticor Biotech Announce First Patient In Liberate Clinical Trial With University Of Birmingham
Brief: Acticor Biotech Says Clinical Trial In Patients With AIS Showed Favorable Safety Profile Of Glenzocimab
Brief: Acticor Biotech Announces Progress In Discussions With EU And U.S Regulatory Agencies
Brief: Acticor Biotech SA Annnounces Initiation Of Patient Enrollment In Green Phase 2/3 Study In Stroke
Brief: Acticor Biotech Gives Update On U.S. Regulatory Discussion With FDA
'Holy grail of stroke treatments' - Kepler starts Acticor with 'buy'